# How the Placebo Response Affects Your Brain and Body

The placebo response is not an illusion or a trick of the mind, but a measurable biological event where your expectations and conditioned habits trigger the release of the body's natural painkillers, dopamine, and mood-elevating chemicals. When you anticipate healing, specific neural circuits—including a newly mapped pathway linking the prefrontal cortex to the brainstem—physically activate to reduce pain, improve motor function, and modulate your immune system. While placebos cannot cure objective pathologies like infections or tumors, they profoundly alter how your brain and body construct the experience of illness, proving that the context of care is an active medical ingredient.



## The Evolution of Placebo Science

For the better part of the twentieth century, modern medicine treated the placebo effect as an annoyance. Researchers viewed it as a statistical ghost—an inconvenience that needed to be subtracted in clinical trials so the true, molecular mechanisms of an active drug could be clearly measured [cite: 1]. Placebos were seen merely as deceptive tools designed to trick a control group, ensuring that patients could not consciously bias the outcome of a study [cite: 2, 3]. Under this outdated paradigm, the body was considered a passive recipient of treatment, and healing was thought to be reducible exclusively to pharmacology and physical intervention [cite: 1, 4].

However, the advent of advanced functional neuroimaging, genetic sequencing, and psychoneuroimmunology has fundamentally rewritten this narrative. The placebo response is now universally recognized by researchers as a potent, psychobiological phenomenon [cite: 5, 6]. It reveals that the human nervous system is an active, predictive engine that continuously translates environmental cues—such as a doctor’s reassuring tone, the sterile smell of a clinic, or the ritual of swallowing a pill—into profound physiological changes [cite: 1, 7]. 

Far from being "just in your head," the placebo response is physically rooted in the biology of the brain and body. By tracing the exact neural circuits that light up during a placebo response and mapping the chemical neurotransmitters that flood the nervous system, scientists have proven that belief, expectation, and clinical context are physiological forces capable of altering the trajectory of chronic diseases [cite: 1, 5, 8].

## The Anatomy of Belief: Mapping the Placebo Brain

When a patient takes an inert substance believing it to be a potent drug, their brain does not remain idle. Functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) scans consistently show that placebo treatments fundamentally alter metabolic activity within distinct, measurable brain networks [cite: 9]. The areas most consistently engaged involve complex matrices responsible for pain modulation, emotional regulation, and cognitive prediction.

### The Prefrontal Cortex and the Expectation Engine

The genesis of the placebo response largely resides in the prefrontal cortex, the evolutionary seat of human reasoning, planning, and conscious expectation [cite: 9, 10]. When a medical professional provides a positive prognosis, the dorsolateral prefrontal cortex begins constructing a predictive model of healing [cite: 11]. 

Because the brain functions as a prediction machine—preferring that internal sensations match its external models—this expectation generates top-down signals that cascade into deeper, older regions of the brain. The prefrontal cortex communicates with the anterior insula, which processes bodily sensations, and the nucleus accumbens, which governs reward anticipation, effectively priming the nervous system to experience relief before any chemical has entered the bloodstream [cite: 9, 12].

### The Cortico-Ponto-Cerebellar Pathway

In 2024, researchers achieved a monumental breakthrough in understanding the exact physical architecture of placebo-induced pain relief, an effect known clinically as placebo analgesia. A landmark study published in the journal *Nature* managed to trace the underlying neural circuits of the placebo response with single-cell precision [cite: 13, 14, 15]. 

To simulate the human expectation of pain relief, scientists conditioned laboratory mice by moving them from a painfully hot floor environment (48°C) to a comfortably cool chamber (30°C). Over several days, the mice learned to strongly expect relief upon entering the second chamber. When researchers subsequently heated the floors in both chambers to a painful level, the conditioned mice still exhibited prolonged pain relief behaviors in the second chamber—a classic, observable placebo response [cite: 13, 16].

By closely monitoring the brain activity of these mice in real-time, researchers identified a previously unknown pathway connecting the higher and lower brain. Neurons within the rostral anterior cingulate cortex (rACC)—a region at the front of the brain heavily tied to the expectation of pain relief—fired intensely, projecting signals down to the pontine nucleus (Pn) located in the brainstem [cite: 14, 15].

[image delta #1, 0 bytes]

 

The pontine nucleus serves as a critical connector to the cerebellum, a region mostly famous for coordinating physical movement. Crucially, the researchers discovered that the pontine nucleus was exceptionally dense with pain-modulating opioid receptors (specifically, Oprd1-expressing neurons) [cite: 13, 14, 16]. When the scientists used advanced optogenetic tools to inhibit this specific rACC-to-Pn pathway, the mice completely lost their placebo pain relief. Conversely, artificially activating this exact circuit provided significant pain relief even when the mice had undergone no psychological conditioning at all [cite: 15]. This discovery rewrote anatomical textbooks, demonstrating that the cerebellum is deeply involved in cognitive pain modulation and the physical manifestation of belief [cite: 16, 17].

### Amygdala Downregulation and Emotional Control

Beyond managing pain, the placebo effect profoundly influences emotional and psychological distress. In clinical trials treating psychiatric conditions like social anxiety disorder (SAD) and generalized anxiety disorder (GAD), patients taking placebos often report massive, life-altering reductions in stress [cite: 9, 18]. 

Neuroimaging reveals exactly how this happens. During placebo-induced anxiety relief, there is a sharp and sustained decrease in the metabolic activity of the amygdala, the almond-shaped cluster of nuclei that serves as the brain's primary fear, threat, and emotion processing center [cite: 8, 18]. The cognitive expectation of feeling calmer signals the prefrontal cortex to exert inhibitory control over the amygdala, effectively forcing the brain's alarm system to power down. This proves that placebo anxiolysis is not merely a change in attitude, but a functional deactivation of the brain's panic circuitry [cite: 8, 18].

## The Chemical Messengers of Healing

The complex physical circuits of the brain rely entirely on chemical messengers to communicate and exert their effects on the body. The placebo response is defined by the rapid release of several distinct neurotransmitters, and the specific cocktail of chemicals released depends heavily on the condition being treated and the precise expectations of the patient.

### Endogenous Opioids and the Pain Matrix

The most rigorously studied and understood mechanism of the placebo effect is its ability to trigger the release of endogenous opioids. These are the body's natural, internally manufactured painkillers, which include endorphins and enkephalins [cite: 8, 12]. 

When a patient takes a pill that they believe is a powerful analgesic for a severe headache or chronic back pain, the brain signals the release of these endorphins. They flood into the periaqueductal gray (PAG) and down into the spinal cord, binding tightly to mu-opioid receptors. This physical binding actually blocks nociceptive pain signals from traveling up the spinal cord to reach conscious awareness [cite: 8, 19]. This endogenous release is so identical to pharmaceutical pain relief that if a patient is given naloxone—a drug that blocks opioid receptors and is commonly used to reverse heroin overdoses—their placebo pain relief is instantly wiped out, proving the effect relies on actual opioid chemistry [cite: 8, 19].

### Dopamine, Reward, and Parkinson's Disease

While the opioid system primarily manages pain inhibition, the dopaminergic system governs reward anticipation, motivation, and motor control [cite: 8, 20]. Dopamine pathways are heavily activated when a patient anticipates a clinical benefit, acting as a massive neurochemical "reward" signal [cite: 21]. 

This mechanism is most vividly observable in Parkinson's disease, a severe neurodegenerative disorder caused by the progressive death of dopamine-producing neurons in the substantia nigra. When Parkinson's patients are given a placebo that they firmly believe to be their levodopa medication, PET scans reveal a massive surge of endogenous dopamine release in the striatum, specifically within the caudate and putamen [cite: 8, 19, 20, 21]. 

This chemical surge displaces radioactive tracers on the scans by up to 19 percent, a physiological change so powerful that it visibly reduces the patients' muscle rigidity and physical tremors [cite: 11, 20]. It provides undeniable proof that the strong expectation of a drug can command the brain to manufacture and deploy the missing chemical itself [cite: 8, 12].

### Serotonin, Cannabinoids, and Mood Regulation

The biological versatility of the placebo response allows it to hijack other major neurotransmitter systems depending on the context. In some specific forms of pain relief, placebos bypass the opioid system entirely and instead activate the body's endocannabinoid system, utilizing CB1 receptors to diminish pain [cite: 7, 8]. In treatments involving depression, mood disorders, and anxiety, placebos robustly engage the serotonin system to help regulate emotional distress, mimicking the exact pathways targeted by selective serotonin reuptake inhibitors (SSRIs) [cite: 9, 10, 18]. 

### The Nocebo Effect and Cholecystokinin (CCK)

This neurochemical versatility also possesses a darker, equally powerful counterpart. When a patient is informed that a treatment may cause harm, or when they hold deep anxieties about potential side effects, they frequently experience the *nocebo* effect [cite: 1, 10]. 

Negative expectations physically trigger the release of cholecystokinin (CCK), a hormone and neurotransmitter that actively antagonizes and overrides the body's opioid system [cite: 7, 19, 22]. This release heightens the perception of pain (hyperalgesia) and can generate very real, debilitating side effects like severe nausea, dizziness, or jitteriness out of thin air [cite: 19, 23]. The nocebo effect underscores a critical ethical dilemma in medicine: the words a doctor uses to describe a drug's potential side effects can literally synthesize those adverse events in the patient's body [cite: 1, 23].

| Medical Condition / Context | Primary Neurotransmitters Involved | Key Brain Regions Activated/Modulated | Typical Symptoms Relieved or Altered |
| :--- | :--- | :--- | :--- |
| **Pain Syndromes (Analgesia)** | Endogenous opioids (Endorphins), Cannabinoids | rACC, Pontine Nucleus, PAG, Insula | Aching, hyperalgesia, surgical recovery [cite: 8, 15] |
| **Parkinson's Disease** | Dopamine | Striatum (Caudate, Putamen), Nucleus Accumbens | Motor stiffness, resting tremors, bradykinesia [cite: 19, 20] |
| **Anxiety & Depression** | Serotonin, Dopamine | Amygdala (downregulated), Prefrontal Cortex | Emotional distress, acute fear response [cite: 9, 18] |
| **Negative Expectations (Nocebo)** | Cholecystokinin (CCK) | Hippocampus, Amygdala (hyperactivated) | Increased pain sensitivity, nausea, fatigue [cite: 19, 23] |

## Is the Placebo Effect in Your DNA? Unlocking the "Placebome"

If placebos are powerful enough to mimic opioids and synthesize dopamine, a persistent question arises: why doesn't everyone respond to a placebo equally? Some patients experience miraculous recoveries on sugar pills, while others feel absolutely nothing. 

Researchers have recently discovered that the propensity to experience a placebo effect is heavily predetermined by human genetics—a burgeoning field of study that scientists have officially dubbed the "placebome" [cite: 9, 24, 25]. Because the placebo response relies entirely on specific neurochemical pathways, slight inherited variations in the genes that build those pathways can make a person exceptionally receptive, or completely immune, to placebo interventions [cite: 5, 9].

### Key Genetic Polymorphisms

Scientists have isolated a growing list of genetic polymorphisms that dictate placebo responsiveness, primarily focusing on the dopaminergic, opioid, serotonergic, and endocannabinoid systems [cite: 22, 24].

*   **OPRM1 (rs1799971):** This specific gene codes for the mu-opioid receptor, the exact cellular lock that endogenous endorphins fit into. Individuals carrying a specific variant (the A/A carrier combination) produce receptors that bind much more effectively to the endorphins released during a placebo response. Consequently, these individuals experience dramatically higher levels of placebo-induced pain relief compared to those with other genetic combinations [cite: 24, 25, 26].
*   **COMT (rs4680):** This gene regulates an enzyme (catechol-O-methyltransferase) responsible for breaking down dopamine in the prefrontal cortex. People possessing a variant that results in higher, sustained dopamine levels (the met/met variant) tend to have much stronger and longer-lasting placebo responses across conditions ranging from irritable bowel syndrome (IBS) to idiopathic chronic pain [cite: 24, 26]. 
*   **FAAH (rs324420):** This gene dictates the breakdown of natural endocannabinoids in the nervous system. Certain missense mutations (Pro129Thr) significantly increase the baseline amount of natural cannabinoids available in the brain, priming the patient for heightened placebo analgesia [cite: 24].
*   **TPH2:** Polymorphisms in this serotonin-related tryptophan hydroxylase-2 gene have been directly linked to a patient's capacity to modulate amygdala activity. Patients with specific variants of this gene are significantly more likely to experience clinical anxiety relief from placebo treatments [cite: 18, 22].

Fascinatingly, these genes can interact. When individuals possess a combination of multiple high-responder variants—such as carrying both the COMT met/met variant and the OPRM1 A/A variant—they can report a magnitude of placebo-induced pain reduction that is four to six times higher than individuals with opposite, low-responder genetic profiles [cite: 24, 26]. 

### Transcriptomics and Gene Expression

Inherited DNA is only part of the story; recent research has pushed the boundaries of the placebome by exploring gene *expression*—how genes are actively turned on or off in real-time. 

In a recent highly sophisticated study, researchers took blood samples from chronic pain patients undergoing an intensive placebo conditioning trial. By performing total RNA sequencing, the researchers identified 667 differentially expressed genes (DEGs) that strongly correlated with placebo responsivity [cite: 24]. 

Patients who exhibited the strongest placebo relief showed significant upregulation in specific genes, including FBXL15, PI3, TNFRSF4, and CCDC85B [cite: 24, 26]. Interestingly, many of these highly expressed genes are heavily involved in deeper biological processes entirely separate from the nervous system, such as cellular division, RNA metabolism, ribosome biogenesis, and the survival of immune T-cells [cite: 24, 26]. This transcriptomic data strongly hints at a profound, systemic link between the brain's cognitive expectation of relief and the body's fundamental cellular environment.

## Psychology of Healing: Expectation vs. Conditioning

The biological and genetic machinery of the placebo effect lies dormant until it is given a psychological spark. In clinical settings, this spark generally comes from two distinct, yet overlapping mechanisms: conscious expectation and unconscious conditioning [cite: 12, 20, 27].

### The Power of Conscious Expectation and Ritual

Expectation is the explicit, cognitive anticipation of a future clinical outcome [cite: 12]. When an authoritative physician hands a patient a brightly colored capsule and confidently states, "This is a highly advanced, newly approved medication that will drastically reduce your pain," the patient's prefrontal cortex instantly builds a predictive model of healing and comfort [cite: 3]. 

Because the brain functions as a predictive organism, it deploys physiological changes to ensure the body aligns with this consciously expected outcome [cite: 1]. The magnitude of this expectation is heavily influenced by what medical anthropologists call the "therapeutic ritual"—the perceived expertise of the provider, the gravity of the clinical environment, the branding on the pill bottle, and the invasiveness of the procedure [cite: 1, 3]. 

Extensive studies consistently show that two placebo pills work better than one, that placebo injections produce significantly stronger effects than placebo pills, and that sham surgeries (where a patient is cut open and sutured without anything being repaired) produce the most massive placebo effects of all [cite: 3, 9]. This occurs because complex, invasive interventions carry a much heavier psychological weight of expected healing, commanding a larger neurochemical response from the brain.

### Pavlovian Conditioning in the Body

While expectation requires conscious thought and belief, conditioning is entirely unconscious and autonomic. Just as Pavlov's famous dogs learned to salivate at the mere sound of a bell, the human body learns to associate the repetitive sensory cues of medical treatment—the antiseptic smell of a hospital room, the physical shape and taste of a pill, the sting of a needle—with a specific biological response [cite: 9, 27]. 

If a patient takes an active pharmaceutical painkiller every day for two weeks, their body biologically associates the ritual of swallowing that pill with the onset of opioid receptor activation. If the active pill is secretly swapped for an identical sugar pill on the fifteenth day, the body will still release a flood of endogenous endorphins out of pure physiological habit [cite: 12, 20]. Conditioning is incredibly powerful because it bypasses conscious skepticism. It is responsible for generating placebo responses in biological domains that patients cannot consciously control, such as hormone secretion, blood pressure, and immune system activity [cite: 12, 20].

### Psychoneuroimmunology: Training the Immune System

The reality of autonomic conditioning proves that the placebo effect extends far beyond the central nervous system. The rapidly growing field of psychoneuroimmunology has demonstrated that the brain's activity maintains direct, mutual communication with the peripheral immune and endocrine systems [cite: 8, 20, 27]. 

Through Pavlovian conditioning, the immune system can literally be "trained." In landmark medical experiments, subjects were repeatedly given a powerful immunosuppressive drug alongside a strongly flavored, novel drink (acting as the conditioned stimulus). After several days of pairing, the active drug was secretly removed, but the flavored drink was administered alone. Astoundingly, the subjects' immune systems still suppressed themselves [cite: 20, 27]. 

The brain had recognized the taste of the drink, activated the insular cortex and amygdala, and deployed noradrenaline to force the immune system to mimic the drug's effect based purely on sensory cues [cite: 20, 27]. Furthermore, in clinical studies treating allergic rhinitis and asthma, placebo treatments have successfully reduced objective markers of inflammation, such as pro-inflammatory cytokines in the bloodstream, proving that the mind's expectations can alter the body's defensive chemistry [cite: 9, 28]. 

## How Placebos Impact Clinical Trials

The massive biological power of the placebo response presents a severe, multi-billion-dollar dilemma for modern medical research. In randomized controlled trials (RCTs), new drugs must prove they are significantly more effective than a placebo to gain regulatory approval [cite: 3]. However, this is becoming increasingly difficult.

### The Creeping Placebo Effect in Psychiatry

Over the last few decades, the baseline placebo response in clinical trials has grown steadily stronger, a phenomenon particularly acute in wealthy nations like the United States [cite: 3, 29]. As direct-to-consumer drug advertising has skyrocketed, societal expectations of medical miracles have vastly increased, inflating the placebo response and making it much harder to prove that new drugs actually work [cite: 3, 30].

This challenge is most pronounced in psychiatry and neurology. In extensive meta-analyses of psychiatric trials, placebo treatments yield massive, clinically meaningful improvements in conditions like Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) [cite: 9, 30]. Often, over half of the symptom improvement seen in antidepressant trials is driven entirely by the placebo effect [cite: 27, 30]. Interestingly, the magnitude of the placebo response varies by the pathology of the illness; while it is exceedingly high in depression and anxiety, it remains much lower and more modest in trials for schizophrenia and Obsessive-Compulsive Disorder (OCD) [cite: 30, 31]. 

### Geographic and Socioeconomic Influences

The context of care heavily influences trial outcomes globally. Recent large-scale analyses of clinical trials for conditions like Rheumatoid Arthritis, Psoriatic Arthritis, and Crohn's disease have uncovered a startling geographic gradient [cite: 29, 32]. 

Researchers found that in trials conducted in countries with a lower Gross National Income (GNI) or Human Development Index (HDI), the placebo response rates are significantly higher than in wealthier nations [cite: 29]. This is theorized to be because trial participants in lower-resource settings receive a level of intensive, empathetic medical attention and frequent monitoring during the trial that vastly exceeds the standard background care available in their region. This dramatic upgrade in the context of care serves as a massive psychological expectation boost, inflating the placebo response and complicating the global evaluation of biologic drugs [cite: 29]. 

### The Objective Limits of Placebo Healing

Despite its profound reach, the placebo effect is not magic, and it operates within strict biological boundaries. Placebos primarily influence *symptom perception* rather than fundamentally altering the underlying pathophysiology of a severe disease [cite: 3, 8, 30]. 

Placebos are exceptionally effective for conditions mediated by the central nervous system's interpretation of bodily signals. This makes them powerful tools for alleviating pain, chronic fatigue, mild-to-moderate depression, nausea, irritable bowel syndrome, and subjective stiffness [cite: 9, 28, 30]. 

For example, in a recent, rigorous trial treating patients suffering from severe Long COVID fatigue, a sham group receiving a placebo hyperbaric oxygen treatment (HBOT) showed massive, statistically significant improvements in health-related quality of life, energy levels, and social functioning, simply due to the intense ritual of entering a hyperbaric chamber [cite: 33, 34, 35, 36]. 

However, placebos cannot alter objective, non-neurological disease states. A placebo response cannot shrink a cancerous tumor, cure a bacterial infection, clear the COVID-19 virus from the lungs, reverse Alzheimer's plaques, or knit a broken bone back together [cite: 3, 30]. In trials for asthma, a placebo inhaler can make a patient subjectively feel that they are breathing much easier, relieving their panic and distress, but objective spirometry tests will show that their lung airways remain physically restricted [cite: 31].

| Medical Condition | Placebo Response Magnitude in Clinical Trials | Primary Impact Domain |
| :--- | :--- | :--- |
| **Major Depressive Disorder (MDD)** | Very High (Often >50% of drug efficacy) | Subjective mood, motivation, energy [cite: 9, 27, 30] |
| **Pain Syndromes (e.g., Osteoarthritis)** | High (Consistent and robust) | Subjective pain intensity, mobility [cite: 9, 24, 28] |
| **Long COVID (Fatigue & Brain Fog)** | High (Major quality of life improvements) | Subjective energy, cognitive clarity [cite: 33, 35, 36] |
| **Crohn's Disease** | Moderate (approx. 18-33% clinical remission) | Subjective cramping, but rarely mucosal healing [cite: 29, 37] |
| **Schizophrenia / OCD** | Low | Limited impact on deep neurological pathology [cite: 30, 31] |
| **Cancer / Bacterial Infections** | Zero | No impact on objective tumor shrinkage or bacterial clearance [cite: 3] |

## The Rise of Open-Label Placebos

Historically, the medical establishment believed that deception was strictly necessary for a placebo to work. The assumption was simple: if a patient knew the pill was a dummy, their expectation of healing would vanish, and the biological effect would break [cite: 2, 4]. This belief severely limited the clinical use of placebos, as lying to patients violates modern medical ethics.

### Healing Without Deception

However, over the last decade, pioneering research into "Open-Label Placebos" (OLPs) has completely shattered this assumption. In an OLP trial, doctors hand patients a bottle of pills and explicitly say, "These are placebo pills made of inert substances like sugar. They contain no medicine. However, clinical studies show they can still produce significant relief through mind-body healing processes" [cite: 2, 4]. 

Astonishingly, patients taking open-label placebos continue to experience significant, measurable symptom reductions. Meta-analyses of numerous randomized controlled trials (RCTs) confirm that OLPs yield positive effects across a variety of health-related outcomes, demonstrating profound efficacy in treating Irritable Bowel Syndrome (IBS), chronic lower back pain, migraine, allergic rhinitis, and depression [cite: 2, 9, 28]. 

### The Bayesian Brain and Embodied Cognition

How is it possible that the body heals itself when the conscious mind knows the treatment is fake? Neuroscientists and psychologists point to the concepts of the "Bayesian brain" and embodied cognition [cite: 2]. 

The brain acts as a Bayesian inference engine, constantly predicting sensory inputs based on past experiences. The mere physical act of engaging in a medical ritual—taking the time to swallow a pill twice a day, interacting with an empathetic healthcare provider, and stepping into the structured environment of a clinic—sends an enormous, unconscious signal of safety to the nervous system [cite: 1, 2]. 

This ritual generates a "prediction error" that updates the brain's internal model from "I am in danger and sick" to "I am actively being cared for" [cite: 1, 2]. It grants the nervous system permission to stop sounding the biological alarm of chronic pain, nausea, or anxiety, successfully triggering the release of endorphins and dopamine regardless of the patient's conscious, intellectual skepticism about the sugar pill [cite: 1].

## Bottom line

The placebo response is a genuine, measurable biological process where the brain translates the expectation of healing into physical reality. By triggering the release of endogenous opioids, dopamine, and serotonin, and by routing signals through specialized neural pathways like the cortico-ponto-cerebellar circuit, placebos can profoundly reduce pain, improve motor function, and ease psychological distress. While the effect is heavily constrained by an individual's genetics (the placebome) and cannot cure objective pathologies like cancer or infections, it provides undeniable proof that the context of medical care—trust, ritual, and communication—is a vital, active catalyst for human health.

## Sources
1. [Script Concordance Test and uncertainty in clinical practice](https://pmc.ncbi.nlm.nih.gov/articles/PMC12973566/)
2. [The Paradox of Self-Deceit](https://medium.com/@krigerbruce/the-paradox-of-self-deceit-53fa9feb75b2)
3. [Open-Label Placebo: Reflections on a Research Agenda](https://www.researchgate.net/publication/328135664_Open-Label_Placebo_Reflections_on_a_Research_Agenda)
4. [Frontiers in Psychiatry: Placebo theories](https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1474558/full)
5. [Placebo and the law of identification](https://www.researchgate.net/publication/387231131_Placebo_and_the_law_of_identification)
6. [Lancet Public Health report on neurobiology](https://public-pages-files-2025.frontiersin.org/research-topics/69473/pdf)
7. [Systematic review on post-COVID cognitive impairment](https://www.researchgate.net/publication/384387947_Research_evidence_on_the_management_of_the_cognitive_impairment_component_of_the_post-COVID_condition_a_qualitative_systematic_review)
8. [Hyperbaric oxygen for long covid trial](https://bmjopen.bmj.com/content/15/4/e094386)
9. [Electromagnetic energy and health](https://www.mdpi.com/2076-3417/16/8/3627)
10. [Synaptic pruning and future neuroscience research](https://pmc.ncbi.nlm.nih.gov/articles/PMC12694624/)
11. [Genetics and the Placebome](https://pmc.ncbi.nlm.nih.gov/articles/PMC12861086/)
12. [Pharmacogenetic studies and placebo responsiveness](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1775522/full)
13. [Neurobiology of the placebo effect and Parkinson's](https://smw.ch/index.php/smw/article/view/2865)
14. [Genetic variants and placebo analgesia](https://pmc.ncbi.nlm.nih.gov/articles/PMC11251865/)
15. [Determinants of placebo and nocebo responses](https://www.tandfonline.com/doi/full/10.1080/17437199.2025.2471792)
16. [Physiological responses to placebo](https://www.mdpi.com/2227-9032/12/22/2314)
17. [Mechanisms underlying placebo effect](https://pmc.ncbi.nlm.nih.gov/articles/PMC3130395/)
18. [Umbrella review of placebo mechanisms](https://pmc.ncbi.nlm.nih.gov/articles/PMC10582987/)
19. [Brain circuits in placebo](https://academic.oup.com/brain/article/131/11/2812/367445)
20. [Hyperbaric oxygen placebo trial](https://pmc.ncbi.nlm.nih.gov/articles/PMC9854077/)
21. [Gaps in Long COVID treatments research](https://wellcomeopenresearch.org/articles/9-358/pdf)
22. [OM-85 for respiratory tract infections](https://pmc.ncbi.nlm.nih.gov/articles/PMC6708164/)
23. [Long COVID therapeutic strategies](https://www.benthamdirect.com/content/journals/cmc/10.2174/0109298673389691250709181809?crawler=true&mimetype=application/pdf)
24. [The Placebome Overview](https://www.researchgate.net/publication/397060286_The_placebome)
25. [Transcriptomic profiles associated with placebo](https://pmc.ncbi.nlm.nih.gov/articles/PMC11251865/)
26. [NIH Placebo Workshop 2024](https://www.nimh.nih.gov/news/media/2024/day-two-placebo-workshop-translational-research-domains-and-key-questions)
27. [OPRM1 rs1799971 and COMT rs4680 markers](https://www.researchgate.net/publication/327148897_The_Opioid_Receptor_Mu_1_OPRM1_rs1799971_and_Catechol-O-methyltransferase_COMT_rs4680_as_genetic_markers_for_placebo_analgesia)
28. [Placebo and nocebo effects neuroscience](https://www.researchgate.net/publication/397142373_Placebo_and_nocebo_effects)
29. [NIH: Brain circuit for placebo pain relief](https://www.nih.gov/news-events/nih-research-matters/scientists-find-brain-circuit-placebo-pain-relief)
30. [Newly discovered neural circuit for placebo](https://migrainecollaborative.org/a-newly-discovered-neural-circuit-for-placebo-pain-relief)
31. [ScienceDaily: Placebo pain relief circuit](https://www.sciencedaily.com/releases/2024/07/240724123119.htm)
32. [Review of Neural circuit basis of placebo pain relief](https://www.oaepublish.com/articles/and.2024.26)
33. [Neural circuit basis of placebo pain relief (Nature 2024)](https://www.researchgate.net/publication/382543233_Neural_circuit_basis_of_placebo_pain_relief)
34. [How does the placebo effect work? (PBS Reactions)](https://www.youtube.com/watch?v=JcPwIQ6GCj8)
35. [Mechanism of placebo effect](https://ijcep.org/index.php/ijcep/article/download/185/163/)
36. [Physiological and clinical neurological responses](https://pmc.ncbi.nlm.nih.gov/articles/PMC11593399/)
37. [The placebo effect and the brain](https://www.journalmeddbu.com/full-text/211)
38. [Time course of placebo response](https://www.researchgate.net/figure/Typical-time-course-of-placebo-response-The-numbers-1-2-and-3-stand-for-subject_fig4_330174442)
39. [Placebo effect in injective approaches](https://www.mdpi.com/2077-0383/14/4/1294)
40. [Clinical practice guidelines for interventional techniques](https://www.painphysicianjournal.com/current/pdf?article=MTg3Mg%3D%3D&journal=74)
41. [EMF and placebo effects](https://health.ec.europa.eu/document/download/87a057e5-0cb3-405f-8f22-f708c624c99d_en?filename=followup_cons_emf2022_en_3.pdf)
42. [Sarcopenia and surgical outcomes](https://pmc.ncbi.nlm.nih.gov/articles/PMC10720826/)
43. [Clinical trial on inflammatory diseases](https://clinicaltrials.gov/study/NCT05374785)
44. [Hyperbaric medicine and placebo effect](https://www.dhmjournal.com/images/55/DHM_Vol55No2.pdf)
45. [Protein supplementation and bone health](https://www.surrey.ac.uk/people/susan-lanham-new)
46. [RTI occurrences in placebo group](https://pmc.ncbi.nlm.nih.gov/articles/PMC6708164/)
47. [Management of post-COVID cognitive impairment](https://www.researchgate.net/publication/384387947_Research_evidence_on_the_management_of_the_cognitive_impairment_component_of_the_post-COVID_condition_a_qualitative_systematic_review)
48. [Post-acute COVID-19 syndrome trial](https://pmc.ncbi.nlm.nih.gov/articles/PMC9854077/)
49. [AHRQ review on systemic HBOT](https://www.aetna.com/cpb/medical/data/100_199/0172.html)
50. [Radiofrequency Ablation for Liver Metastases](https://pmc.ncbi.nlm.nih.gov/articles/PMC8656541/)
51. [AHA Heart disease and stroke statistics](https://www.ahajournals.org/doi/pdf/10.1161/cir.0000000000000152)
52. [GLP-1 receptor agonism clinical trial](https://clinicaltrials.gov/study/NCT05478707)
53. [Evidence based clinical practice guidelines](https://www.painphysicianjournal.com/current/pdf?article=MTg3Mg%3D%3D&journal=74)
54. [Long-term care insurance impacts](https://pmc.ncbi.nlm.nih.gov/articles/PMC13104257/)
55. [SCHEER report and EMF exposure](https://health.ec.europa.eu/document/download/87a057e5-0cb3-405f-8f22-f708c624c99d_en?filename=followup_cons_emf2022_en_3.pdf)
56. [Gaps in Long COVID treatments scoping review](https://www.researchgate.net/publication/382199282_Gaps_in_Long_COVID_treatments_research_A_scoping_review)
57. [Alpelisib plus endocrine therapy](https://www.icr.ac.uk/research-and-discoveries/find-a-researcher/test-researcher-profile-detail/dr-nicholas-turner)
58. [HBOT and immune response in Long COVID](https://openarchive.ki.se/ndownloader/files/48952801)
59. [HBOT trial for ME/CFS](https://clinicaltrials.gov/study/NCT06118138)
60. [Long COVID fatigue scoping review](https://pmc.ncbi.nlm.nih.gov/articles/PMC11647363/)
61. [Long COVID fatigue assessment](https://bmjopen.bmj.com/content/14/12/e088530)
62. [Hyperbaric oxygen therapy for long covid](https://www.springermedizin.de/covid-19/hyperbaric-oxygen-therapy-for-long-covid-hot-loco-an-interim-saf/23942638)
63. [Systematic review of randomized placebo-controlled trials](https://www.canjsurg.ca/custom-print/14085)
64. [Postoperative recurrence prevention in Crohn's disease](https://www.mdpi.com/1648-9144/62/5/883)
65. [Network meta-analysis for Crohn's disease](https://www.researchgate.net/publication/396033258_Systematic_review_and_network_meta-analysis_comparing_the_efficacy_of_conventional_therapy_and_biologics_to_prevent_endoscopic_postoperative_recurrence_in_patients_with_Crohn's_disease)
66. [TNF antagonist monotherapy meta-analysis](https://www.mdpi.com/2077-0383/14/23/8435)
67. [Infliximab for prevention of CD recurrence](https://pmc.ncbi.nlm.nih.gov/articles/PMC6311309/)
68. [AHRQ and FDA guidelines on clinical trials](https://clinicaltrials.gov/study/NCT06118138)
69. [Aetna HBOT clinical policy bulletin](https://www.aetna.com/cpb/medical/data/100_199/0172.html)
70. [AHA Statistical report](https://www.ahajournals.org/doi/pdf/10.1161/cir.0000000000000152)
71. [Comparative Effectiveness Reviews by AHRQ](https://pmc.ncbi.nlm.nih.gov/articles/PMC8656541/)
72. [Placebo mechanisms across physiological systems](https://pmc.ncbi.nlm.nih.gov/articles/PMC11593399/)
73. [Psycho-neuro-endocrine-immune basis of placebo](https://pdfs.semanticscholar.org/2b2c/e8195a2e88952ff4da7f62336c9a4f4fdab8.pdf)
74. [Review of Placebo Effect Factors](https://www.researchgate.net/publication/385004643_Review_of_the_Placebo_Effect_Psychological_and_Biological_Factors/fulltext/6711460624a01038d0f142cb/Review-of-the-Placebo-Effect-Psychological-and-Biological-Factors.pdf)
75. [Placebo mechanism in neurological conditions](https://biokb.lcsb.uni.lu/publications/13a5fd80-3522-11e8-9192-001a4a160175)
76. [Artificial intelligence to address placebo response](https://innovationscns.com/artificial-intelligence-address-placebo-response/)
77. [Placebo and nocebo determinants summary](https://www.tamingthesru.com/blog/journal-club-placebo-and-nocebo-use-in-the-emergency-department)
78. [Placebo response rates across psychiatric disorders](https://www.psychiatrictimes.com/view/placebo-response-rates-vary-across-psychiatric-disorders)
79. [Vera synthesis on rising placebo responses](https://verahealth.ai/news/c1a49b97)
80. [First10EM Research Roundup](https://first10em.com/research-roundup-for-january-2025/)
81. [Trial files post on liberal fluid intake](https://medicinepods.com/trial-files-post/trial-files-liberal-fluid-intake-vs-fluid-restriction-in-chronic-heart-failure-semaglutide-in-mash-and-first-line-treatment-of-pulmonary-sarcoidosis-with-prednisone-or-methotrexate/)
82. [Placebo-based amygdala modulation](https://psychiatryonline.org/doi/10.1176/appi.neuropsych.19030077)
83. [Psychiatric pharmacogenomics](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1775522/full)
84. [Candidate genes involved in dopaminergic pathways](https://pmc.ncbi.nlm.nih.gov/articles/PMC11251865/)
85. [Placebo responses and effects on treatment outcomes](https://www.tandfonline.com/doi/full/10.1080/17437199.2025.2471792)
86. [Genetic predictions and the placebome](https://pmc.ncbi.nlm.nih.gov/articles/PMC12322037/)
87. [ACOEM guidelines](https://www.painphysicianjournal.com/current/pdf?article=MTg3Mg%3D%3D&journal=74)
88. [Workplace violence and training effectiveness](https://pmc.ncbi.nlm.nih.gov/articles/PMC11800325/)
89. [HIV PrEP adherence systematic review](https://www.iasociety.org/sites/default/files/JIAS/JIAS_Vol22-S4_complete_file.pdf)
90. [Caregivers' well-being in Japan](https://www.researchgate.net/publication/378553375_The_impact_of_reducing_formal_care_benefits_on_caregivers'_well-being_evidence_from_Japan)
91. [HBOT for long COVID fatigue](https://pubmed.ncbi.nlm.nih.gov/34862223/)
92. [Recurrent respiratory infections in children](https://pmc.ncbi.nlm.nih.gov/articles/PMC6708164/)
93. [SF-36 questionnaire results for long COVID](https://pmc.ncbi.nlm.nih.gov/articles/PMC12322159/)
94. [GLP-1 dulaglutide clinical trial masking](https://clinicaltrials.gov/study/NCT05478707)
95. [PrEP implementation project](https://pmc.ncbi.nlm.nih.gov/articles/PMC12421193/)
96. [WHO PrEP guidelines](https://www.dovepress.com/the-current-and-future-impact-of-who-guidance-on-global-hiv-pre-exposu-peer-reviewed-fulltext-article-IDR)
97. [OPRM1 rs1799971 and COMT rs4680 interactions](https://pmc.ncbi.nlm.nih.gov/articles/PMC11251865/)
98. [Distribution of placebo effects](https://www.researchgate.net/figure/Distribution-of-placebo-effects-in-the-Discovery-and-Validation-cohorts-Individual_fig3_380395067)
99. [Genetics and the placebo effect (placebome)](https://smw.ch/index.php/smw/article/view/2865)
100. [Serotonin transporter-linked polymorphic region (5-HTTLPR)](https://smw.ch/index.php/smw/article/view/2865/4679)
101. [The Placebome association](https://discovery.researcher.life/article/the-placebome/f5c7c8e32433306d8f4097522b7701cd)
102. [VA Evidence Synthesis on Guided Imagery](https://www.hsrd.research.va.gov/publications/esp/guided-imagery-REPORT.pdf)
103. [VA Evidence Synthesis on Video Telehealth](https://www.ncbi.nlm.nih.gov/books/NBK538994/)
104. [VA Evidence Synthesis on Massage Therapy](https://www.hsrd.research.va.gov/publications/esp/evidence-massage-report.pdf)
105. [VA Evidence Synthesis on Women Veterans](https://pmc.ncbi.nlm.nih.gov/articles/PMC8238232/)
106. [GEM Initiative Evidence Mapping](https://www.researchgate.net/figure/GEM-Initiative-Evidence-Mapping-Methods_fig1_51228366)

**Sources:**
1. [medium.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEGnXpPZrvX0qf3Kj69CuVtSFlSfCHLOoRloPMVa7MmBH_NmV4GnVQZxYLEawoGiSmUBzmGDJCKr6yaQvvwleFW34q2A7UoNB8O2Qfq7etJxefRdIjH0kQDT_QuMLyM11jqFxPO_i_LFSc4OAGKw66r_1JW9XYgsi_VSiDCGw==)
2. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFpddJf0Db7EC4vjtAo-SvfztUIUbFA8Lc7NGasKZHt3P_pEkezOwdnSpg8-b2owfR2g-TDcGL8k6NA7F0ti8zdYLpSBqPqTI1Ai4h6I4pfRtJEYCtVW7JsbK2KZzzJYPBugXyfwXVvc0-OLYV7kbSzo46sS6-E-xoL0zmaNVYhliGaC-dh7qQXxsnfrqDa19b6XZEVtiwdYExi2ZA=)
3. [youtube.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFj_AQiTl4-uX9xux24EhYI7_UyNi-Tyv-jIty4RuWta4hmyjacaGQcFL84LkQEWsfNw8BiX58KO6ruYV89UM8eoBUFRnpGkiqIQt-6H9jKU6yBkWWeHnY3to6C0SHt7GCE)
4. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEAudkYUvKWmXfQ5wIx4WH5qbHWmPPiw9E9w1F1SZtmDpN9wxDS25NQVDtlu6F1TA7EXvgwpvau8kLssU9oNDGz6H6UMt32mp_ovX7DA9YS00UedcESbeJjHbUo_F7ODAYgAEh9oOJgVyZKcGh_pfPOaz5Uu00yWH9QYHkX3waKiHBhT2b0MMbaGGy68Ovz)
5. [smw.ch](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQECrUtudm3m11sgQvZdU8ukeJpsNkYJPgYEZyl3xmkeo_6B34oyJ9cLL9kAhsR6rKGqmtTzy8hUOvq6taKOIajJxFGdwWnycMj2YV8aMIXhQpMVcRkgjyVyDGh9txJfqd4fWDPO)
6. [innovationscns.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGH_1YXUxHL4nssdkxNO5GQOb4J5G8njZ_5pVJfUM8y1LhikVlKxUM7vtmXoeBTitvx6A7tdrBChmqXewrg_gHnH8e-6zfHor_Shf7TMWupAjhbbFoscihbLUzhWot0umGzKSmH3baW9O4PK3W-fL3AWL9McNmUGmj6Or_8aa4EJ9IV)
7. [ijcep.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGmVcmWxOrFnEZTZXSkqR81ph1X5cq1x94Vw0QxPDTxpp6yDjWH39qfwcDXgGUSjBaKQiHXVeGG6jS7HXqeDST6Gq6rQxlMfhq4wdvabRnm3w5qdF2HvYrZOhX3mnEm1N8GjgTxLwElA6rNUV7O_f9WYw==)
8. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEUkOYqzL9TlDbp7ClGqd2inhjxYMdiPG6DHIl9_5GZTT4S8P4WPjj4zip0jQHfX7SZCHBKdpTJJa1sshlwVVp7mV-O1Ofj0TFkUmVoLSYsLkrUmvMnlTQL7pg9NrcnvQ==)
9. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFfL-tcxaDHqLQmWd-aK4hg80kC2Ic8WcW_X3YTamZ7GzvfgkvNmFiOSbjs0J3f0Z4KR72YzXdkt8Rjpw-95G2yk_3Si7Q39_A99zvCLkbMqv0fYTHTKunU573ByA8PbA1xyi1SmOP82A==)
10. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGsBDwLj1kCHfkiAMZvMnlxmfbyPSwWdluanWMWXYjF5x3L03kV8hADTehxrWBzHdkEBgBhfsR6jug4hIwo5s0D264Y1Ss9chG32X0n4M23S1MPj87XXC2ufwnU7qQeYiEoypeCLgmzyw==)
11. [oup.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHcnB0_F49a6kPI_iW5B5RJKU_V8S6MIj0ApB-TdbZ1QpI85Xz5UGH9ShCTjpHnuOdUuorOdvWW5GOW8Lvt-TJTI5Z6BjrRRTNXB8mJgAJg5Yl_O_gzDJD0F4CObgsyQTOYBgHI8idf9lmhj9p7Ggg=)
12. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0EwSWuu176H8dDjLLCKiF5axIemHrzqpuBdBFEhJW9SKwfK4EDGIG8YF98HUUj9T7e-mMqsNfCiO2nHWIKZqUCIouUUjgkrEk7avZ5KkkPA7d6M649PQSaxaj6To6ipccfVAFsupdFX45zPKO-xbrwBOEEIZTtKFgu9DKMyFqvMgUc_lgY-r-xzDfMBlHb3ZFDcHK4gLbF1E03iWkiWseUvJs-4K46boI7VUGXmrUa0jzXBKoXnoPmwosYlVcffZQ1X5U6_0-mBh5C-OvcOO3YnwIvrzLeflaHF2vxGqyY8PrUDWuS_qw_a5M_aeEt-4VZ29y6KViKt0lLhji6JjTaK6kBZRLfk0XF1jk_YcugnHKGg==)
13. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF6j6WfqMrSjwhf1S7WbviID2IxDHJVP1JdalGE3eiOAJoOrgCpvodb8pOt9R71e6PJxYctc-2vxWZFiAgNFjiOHUDDl1O7lVL75rwrnbvqcQ7YWREa6zhF5n-deOzTxQ_2NKeNdzO9cB5hR6jHfUOEjvHsNXCdPWYEmMdDkjNKSNMTTw_MH1Ihj5B7_XhRIewG0xjAdqbR5cDVae4=)
14. [sciencedaily.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFaP7u6ChQRvpMV6ZzfuTZRTPIisq_UQjy395wToZkIE6MSVySozbE27tWzusbD754g5c8BMLJfd04rDDqa0l-q8xm_vWPyS68wjhGycxa85O8KgbL-d-nrh_ZBLVu8qkMPscDNiXsGmpL84WTFF1p2ZB9bPQ==)
15. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHcTa9speqdQWhQTw53SB66vfAHG7hFU14ELTRdqLn3qJiV1AQvbKNrM0nZ8W5ijQbys5qUSZhj9InOvcusFH4wfT4Unw73h4SPtRHYKTcr-nt1X0RksJ4YdrVrP12fxpBmV0T7tIsxgJHokIeP7IPU4P-e43KOONB9sCW53_-fSZ4lmP68V651U9MXp-JY1gVFFPpN)
16. [oaepublish.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHIp3p2FKCz91-EKp36TzqITAiygr6ntfnck9Iqx_Bvin8Cfqs_RoBGdcdwQ-9y5CXsyxK3hIEIbvlckt7NlfjebufTSNkuVUspoNrEP-2kOISPxQyy_Agu0U9zCjtCYbe7nj4Wgg==)
17. [migrainecollaborative.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQET8_kE6AGf0SVkQ8Y9d7S_EvrTHQslrJXAZWoiw30knSQzsoo1lLnNLKJpMEZtTskKkfySEFT654mudsM-tsOXzlyW6mvJc6o3ZW6-2W-PXP4rrkTJG3nX7hV4fX5mEgxtM8RRmVwnINZm8gWbU8AbHDaY-Kd8X08z0XIRkNxkiGdrBoo0YPbMw81Czm8Q1JeK)
18. [psychiatryonline.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGdYBZcgc2JiXgEBl-67o_lKGm76wcRuwpoKuJuuoGyeam4atWU-FPJnx_aBtzbPhH9qr8oFkSj9rg-HKMrKwd1G6IRsbmtLjSDhRCwZkaaShhuvquQ4gP9o_iok37tjKI_Xdjx8fQQWsTxD7Sxz-xuWXJ13ByhDw==)
19. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHHe6LatQfl1m5DS3N4SQo0bJgsRwlNAmFHds1LJ2FKUra7etGkgRi9iZMEe_zUX9xQ9yfOyMLWWvMRjPfM79OmtOFhbIa8gnbevdb_XlTir2vDQhX5J-MHKorOKWUfFGUThg_ExAnY)
20. [semanticscholar.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE8zfLlT0hIlQW4BD6_xV3SoEpvmvolwIhEhPBtidtUkSbOLp8VOT3zAGMNYj2k1lTM2DgNaPUlzBqu37T9X34j1X2VC9incpNXFdojFGFuh2sZ8SMQV3JFj2kNh6QpmiYvIt5xWgLXut1U8l8Ht0nfjfiOQE1JW2E3NXrrmiMBUifrD08=)
21. [uni.lu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGLiRfyFp8_nRb_UoLeJsnlZ68_MdiZ160xXmzmd2HJhaWqGXmGagwUFPEkQbXncQINitedaUZMCOeldS0nIHlDid88VtP1dfyHOa1J-98Aj3oBMDwz1tuwOCIPeDfPlz3ZWntdofxWT6r8gev7x45StSRxQZ0Qq1yn21Lb819JxAA=)
22. [smw.ch](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHVHWjvwifbv3Ip8div9LfZAongNWEKi5Z48bHvXt1ni6L35H-XzSbEsR7lq8RHY_FMB5FyHasSh01S9XKOcE1-Wk0iAtNQUYjEY4ZvCi-Y35qhMJfRxPIGnmrVtI8m0g4DkHueJotho0Q=)
23. [tamingthesru.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHWSZmspELj7fs4yCVsQz_Bj8qGxUPE9GbvAf-pBeSGpE6RkgCbVL7einLY1HLa-EXYPWbDyh0XFin-LLnCSEtS3Lr0nq4P_0Bh6AiL9IPmFOUxTqgmVWORsjd-C_lNXvUj98xGic6PUQru3PazMJo08YCZuqj4h41UKpa55rDpUue-PYECIMxP_5AvSHqpNe39mqYSdhPJ)
24. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQETYE5tWnCzMmtPAJaLFpzz_yvM3hVN8q0XOmmn-1HGBS2SItgtIAGWD46eG6qwGkglEIp0jzPL5xlROH3lerGAhWS1UPcwxFozTY0JOS5Q6YqeXoOJkM3K_tRJT191unsd9pGGSDqP-A==)
25. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFMZ-DLBJke4DQZEMa9LPw3nnvk8aTrPeIFvdtxssrjVlhe0-CbhrJSLW81Ntf6dHHd07Jp3lTtoEUVQyvju8sYAuGzUnveFRKRV9gyzfs9mlG8G4zArJc-h2TfI4m3-MtIi86oa7pv13qZEWCuipgkeT_3KikeABPaV6auPYivFOVEj0aTjQhX-DLyeplvVmM7SRGkF7cbmeGGtXXL_xcDg0o8p88pst5Q7do6_SgK1fCA7BP61Ihev9RPVg==)
26. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHeA0EZAeAHlnr652NWBPTAs5Ok51Mp_phFjgkk6ckdN8gzt5vS_RAfzZKCzexICFVj_J7e-aYndPcSUsTjU-DWS-8hcmgaTYUN1Px1zwOg1gAUDRXZsV08FNLPaSzl16RXf1ykNTDdmRCswVs3SWI0IbFctsoTKI6_3s_-Z9g1MMnyTBqYtRZRx8J6Kg0Mh0otYtK-eHdV2iyXbd9QA5nK8QsJGiSkt5w-xH_ecpgdEJsLwbN9s70kKiKbYdt0JyZ58TwLZpER0u-3E6H-oaFoJ8QODAGSSRcaMaN1Jnn7C_FqUFBpQIVF)
27. [journalmeddbu.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEbUyaIRasCpk29JjTNkwHHdHcNeRbjRMgDRtAg2qc83IxK4e_0uLOnEEv3NWbTIjAJHnERU7byvolQRTTsUC2GdD0w4K-_pJF-f3YaViiGikwBUOu0fFIgdDvPz9aMlohj)
28. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGZHpRiiuq-FLV8vSIcTy3HD10xPZSiMl7EdjXIywdIhwwwEB32Q8cz_sQ6G8cWT9fxVS3CEJsMAPDJIIJgDqs7vboo3LAWZfRO88MJLSU-vxr6tXbgVCHIE9Yh8f7Yx6asvGVRWpk4-w==)
29. [verahealth.ai](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGXjeq2Wa1IN2tZLdAaspLFGd9Yii9_DGewnhI3mb_ZOT5OfEZJqQT9Qi4jyD9OcgNJoBbNseqQXut6E9pZeWzqtYZoDVUgqx8gkCj_qgI9AAN333UfP5sHbg==)
30. [psychiatrictimes.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFjz4objsIiIiPUfJq8M6mSPDlSii5HG1MFGb6T0xtQYYcTV9nh4X4Lqp5tlIK3cX8ym5gemMKhGjRwD_bY2dwHmfOk01FF7mYNmom0Pd0QhWLaE4R0F4nPO4ZCAnihvoLKvVCNP0WiLj_AIkduJFasgssUDU9r3WKiyPzUptMsw_Z7c7Cs7toCkOgQidHz9Ldx3MjU)
31. [tandfonline.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEch0dD4gUmqQ73QD6H1yn9MJqeyC0VXW264Kd39e_OL4kx1Ui6ge1KSX2JkIFsQdZSKXnxwOuhIUmMKAyVR1-Su1yYhYmISUNbsi7OKHOe-KtN7ndbOt37F9Br8IB38swbSfqAAuP1VxMhV8QzHf9wLpA3Q1e_WjQ=)
32. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFXwSu9tSV9LQZJC0e2-Hm8dxlu9jdmwqeBHf32lyFgDDx6LXFbCNjnLtM1qWVgAGySMF3kn5VSmr9nB9cftuQfE-GfRT-D3n9rOzusQN_Ponwo6WbFZZ9uWCS59VWFVEIsNOmlFfAsNa1K4yZlcVgCGkIyvvwIO6ugexQIWXDH4lWT-xMY3nJptPdtj1LOuKaOiuWGmBAUDT2PYX0qYMlw5nEXPGn0wuMFvlUeD1hj23wz0Ay4R7NzJgYdmjCN7Muq_zIxN9GjKdzvtEZyCBsBVWH76feb5dIY-aFvcqQrTycxXgXWUlvwEsj-xsLBTg8X8oJ4k3qN_2JwfUNsjOxy-DtS7y531XJ0xv4_Fuik3L8ByLpITmwyy9UIJ522KU1azg==)
33. [bmj.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEe3uGrDblPAG4MEXyM1dNSE3BGKg6wkfX0ZUukaTZgODjBKTd09z0ikzaaCOQ_lt0-MARv_7hQ1GSUQkBz5WCgOiTKrBCo3lZ-X96I2ux8gXfzjkzshk59NpH2dMd1_PUbBQ==)
34. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFtiB34XMKrOvYPImfHCRsSeIQAm8HFLAUjPd7W1g_pm2MdcHmMTB-FYhQs8BgLyRXlaH1JwRY65HCydPtKAJ1E86LlS_oqbws0KpKHxV5MzH3WZW6GGI7Nj_caI2Jjwp_UrHDIXYZT)
35. [ki.se](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHva0lcFgsVpB7OrqzWpWCDiX0drA-6ekOW4hotCCEd_1ngNB9vhrDmfFxg9Vt6jSxKvXvSp5AluIQKwjvC6twxIq5F86qh87bLGVAC4HceZlrgz4PaRHvRpaiSDLJJkQE_zTczFAnaNwHu)
36. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEgvAIa_dGSLAFCKRQgJa0B7l8P-n46yyYYQcaGdj5pE5g-mot0nzroGOxzlA6U6Ci2tfTMJWo12ZRuO5goWPTK02IfXAg-xJ5HmJefb1RpbOHtqJAgQNViGCJzgLLKju8C3JSfCeKROg==)
37. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwZNrDcxCkDS472Okkbgb5lrzQXXhH2QU3iC97RMdccZJ80jwa7JnwPvepxnVx46MtFf-3qlp8OmfCUxPPD2OywfxekmrIGeZ0biNsAVLy4_66fgz8WjxJ2rPvSekgRQ==)